Cargando…

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

We have recently defined “immunogenic modulation,” a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hodge, James W, Kwilas, Anna, Ardiani, Andressa, Gameiro, Sofia R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902115/ https://www.ncbi.nlm.nih.gov/pubmed/24498561 http://dx.doi.org/10.4161/onci.26937

Ejemplares similares

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
por: Gameiro, Sofia R, et al.
Publicado: (2014)

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
por: Ardiani, Andressa, et al.
Publicado: (2014)

Androgen deprivation therapy increases the sensitivity of human prostate carcinoma cells to T cell-mediated lysis through an androgen receptor dependent mechanism
por: Gameiro, Sofia, et al.
Publicado: (2014)

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin
por: Kwilas, Anna R., et al.
Publicado: (2016)

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
por: Demaria, Sandra, et al.
Publicado: (2013)

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
por: Kwilas, Anna R., et al.
Publicado: (2012)

A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
por: Kwilas, Anna R., et al.
Publicado: (2015)

Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy
por: Konda, Prathyusha, et al.
Publicado: (2020)

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack
por: Grenga, Italia, et al.
Publicado: (2015)

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
por: Kwilas, Anna R, et al.
Publicado: (2014)

Effects of Cabozantinib, a small molecule tyrosine kinase inhibitor, on the immune permissiveness of the tumor microenvironment and immune-mediated killing of tumor cells
por: Kwilas, Anna R, et al.
Publicado: (2014)

Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
por: Hunn, Martin K., et al.
Publicado: (2013)

Cancer neoantigens and immunogenicity: mutation position matters
por: Capietto, Aude-Hélène, et al.
Publicado: (2020)

Osteopontin, a possible modulator of cancer stem cells and their malignant niche
por: Rao, Guanhua, et al.
Publicado: (2013)

The emergence of phox-ER stress induced immunogenic apoptosis
por: Garg, Abhishek D., et al.
Publicado: (2012)

Warming up the tumor microenvironment in order to enhance immunogenicity
por: Humbert, Marion, et al.
Publicado: (2018)

Reducing prostaglandin E(2) production to raise cancer immunogenicity
por: Zelenay, Santiago, et al.
Publicado: (2016)

Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
por: Kono, Koji, et al.
Publicado: (2013)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021)

Triple threat treatment: Exploiting the dependence receptor properties of metabotropic glutamate receptor 1 against melanoma
por: Gelb, Tara, et al.
Publicado: (2014)

Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity
por: Garg, Abhishek D, et al.
Publicado: (2013)

A novel facet of tumor suppression by p53: Induction of tumor immunogenicity
por: Li, Hai, et al.
Publicado: (2012)

When defense turns into attack: Antiviral cytidine deaminases linked to somatic mutagenesis in HPV-associated cancer
por: Henderson, Stephen, et al.
Publicado: (2014)

The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions
por: Koido, Shigeo, et al.
Publicado: (2013)

Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors
por: Achour, Abla, et al.
Publicado: (2014)

DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma
por: Ji, Jie, et al.
Publicado: (2015)

The relationship between malignant and tumor-associated cells provides a new strategy for targeted diagnosis and therapy
por: Lu, Xiaoling, et al.
Publicado: (2013)

Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation
por: Koido, Shigeo, et al.
Publicado: (2013)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen
por: Rosental, Benyamin, et al.
Publicado: (2012)

Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone
por: Riganti, Chiara, et al.
Publicado: (2013)

Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore?
por: Roberti, Maria Paula, et al.
Publicado: (2020)

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
por: Song, De-Gang, et al.
Publicado: (2012)

Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies
por: Chen, Lei L., et al.
Publicado: (2012)

Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
por: Rossig, Claudia
Publicado: (2012)

Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy
por: Dondossola, Eleonora, et al.
Publicado: (2014)

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)

What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation
por: Orgaz, Jose L, et al.
Publicado: (2020)

Cancer-associated fibroblasts and macrophages: Friendly conspirators for malignancy
por: Chiarugi, Paola
Publicado: (2013)

Metabolic stressors disrupt proteome homeostasis to suppress malignancy
por: Dai, Chengkai
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hp65ebg00ksqm585tn8vuj6hma